Clinical trials: Pancreatic Cancer Stage III
Pancreatic Cancer
Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Vaccines made from donated tumor cells treated with interferon alfa may make the body build an immune response to and kill pancreatic tumor cells.
- Trial name
- NCT00002773
- Testing
- allogeneic tumor cell vaccine, recombinant interferon alfa, sargramostim
- Where
- United States
- Sponsor
- St. Vincent Medical Center - Los Angeles
Pancreatic Cancer
Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
RATIONALE: Perifosine may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have locally advanced…
- Trial name
- NCT00059982
- Testing
- perifosine
- Where
- 10 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Colorectal Adenocarcinoma, Gastric Adenocarcinoma
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have…
- Conditions
- Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma
- Trial name
- NCT03368963
- Testing
- Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Emory University
Pancreatic Neuroendocrine Tumors (pNET), Pancreatic Neuroendocrine Tumors
Adjuvant Trial in Pancreatic Neuroendocrine Tumors
ADJUPANET is an open label, double arm, multicenter, phase 3 trial that aims to investigate the efficacy of systemic chemotherapy in locally resected aggressive pancreatic neuroendocrine tumors.
- Trial name
- ADJUPANET (NCT07591493)
- Testing
- Adjuvant chemotherapy with Capecitabine-Temozolomide, Active surveillance
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Extrahepatic Bile Duct Cancer, Pancreatic Cancer
Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00010088
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- 50 sites in France, Luxembourg
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer
This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04067960
- Testing
- Biospecimen Collection, Genetic Testing, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7
3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery
This phase I trial is studying the side effects and best dose of 3-AP when given together with radiation therapy in treating patients with stage III pancreatic cancer that cannot be removed by surgery.
- Trial name
- NCT00288093
- Testing
- 3-Dimensional Conformal Radiation Therapy, Triapine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Lung Cancer
Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers
RATIONALE: A disease management program may be more effective than standard therapy in improving quality of life and controlling symptoms in patients with cancer.
- Conditions
- Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- NCT00684801
- Testing
- questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 605 people
- Sponsor
- Case Comprehensive Cancer Center
Pancreatic Neoplasms
Combined Resection vs. Separated Resection After Mobilization of Splenic Vein During Distal Pancreatectomy
Eligible patients will be centrally randomized to either Arm A (resection of the splenic vein after isolation from the pancreatic parenchyma) or Arm B (co-resection of the vein together with the pancreas).
- Trial name
- COSMOS-DP (NCT02871804)
- Testing
- combined resection of the splenic vein, separated resection of the splenic vein
- Where
- Japan
- Volunteers
- 304 people
- Sponsor
- Wakayama Medical University
Pancreatic Cancer
HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer
The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to gemcitabine + capecitabine treatment as adjuvant therapy in patients…
- Trial name
- NCT06217042
- Testing
- HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate, gemcitabine; capecitabine
- Where
- China
- Volunteers
- 524 people
- Sponsor
- Fudan University
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer
This clinical trial tests the safety, side effects, best dose and feasibility of using 64Cu-DOTA A2 scFv-Fc2 DM with positron emission tomography for the imaging of patients with PSCA-expressing pancreatic cancer that has spread…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT07608627
- Testing
- Biospecimen Collection, Copper Cu 64-DOTA-A2DM, Positron Emission Tomography
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Pancreatic Cancer
3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00078975
- Testing
- gemcitabine hydrochloride, triapine
- Where
- 4 sites in Canada
- Volunteers
- 26 people
- Sponsor
- University Health Network, Toronto
Pancreatic Cancer
A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma
Four-drug combo yielded a statistically significant improvement in progression-free survival and overall survival compared to gemcitabine in patients with advanced pancreatic adenocarcinoma.
- Trial name
- PACT-19 (NCT01730222)
- Testing
- cisplatin, capecitabine, gemcitabine
- Where
- Italy
- Volunteers
- 137 people
- Sponsor
- IRCCS San Raffaele
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Pancreatic Cancer
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Phase III Metastatic Pancreatic Cancer
- Trial name
- NCT00844649
- Testing
- Albumin-bound paclitaxel (ABI-007), Gemcitabine
- Where
- 193 sites in United States, Australia and 9 more
- Volunteers
- 861 people
- Sponsor
- Celgene
Locally Advanced Pancreatic Cancer
Pancreatic Locally Advanced Irresectable Cancer Ablation
The aim of the PELICAN trial is to investigate the survival benefit of RFA plus standard palliative chemotherapy as compared to palliative chemotherapy alone in patients with LAPC after 2 months of induction chemotherapy.
- Trial name
- PELICAN (NCT03690323)
- Testing
- Radiofrequency ablation (RFA), FOLFIRINOX, Nab-paclitaxel plus Gemcitabine
- Where
- 2 sites in Netherlands
- Volunteers
- 228 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pancreatic Cancer
Identification of Biomarkers for Early Detection of Pancreatic Cancer
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897494
- Testing
- protein expression analysis, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Resected Pancreatic Adenocarcinoma
Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX
Induction mFOLFIRINOX has become the standard in the management of locally advanced and borderline adenocarcinoma. Following the results of the PREOPANC-01 JASP-05, NEONAX studies it is expected that the neoadjuvant approach will…
- Trial name
- PANACHE 02 (NCT07044453)
- Testing
- Gem/Nabpaclitaxel infusion, mFOLFIRINOX infusion
- Where
- France
- Volunteers
- 390 people
- Sponsor
- University Hospital, Rouen
Pancreatic Cancer
Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine
This crossover trial is performed in advanced and metastatic pancreatic cancer not previously exposed to chemotherapy. The study compares a standard arm with gemcitabine plus erlotinib to an experimental arm with capecitabine…
- Trial name
- NCT00440167
- Testing
- Gemcitabine, Capecitabine, Erlotinib
- Volunteers
- 280 people
- Sponsor
- PD Dr. med. Volker Heinemann
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Pancreatic Cancer
- Trial name
- NCT00266097
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center